At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 53 enrolled
Drug / intervention
Trumenbabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 4, OPEN-LABEL, SINGLE-ARM TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TRUMENBA(REGISTERED) WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS ≥10 YEARS OF AGE
In Brief
A Phase 4 clinical trial evaluating Trumenba for Meningococcal Vaccine. Completed, enrolled 53 participants across 14 sites in 3 countries.
Detailed Summary
The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic and complement-deficient individuals ≥10 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Vaccine
CountriesCzechia, Poland, Turkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartAug 2021
Primary CompletionSep 2023
TodayJul 2026
First PostedMay 20, 2021
Enrollment StartAug 18, 2021
Primary CompletionSep 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.1 years ago
Interventions
Trumenbabiological
Bivalent recombinant lipoprotein 2086 vaccine